Connect your AI

Wave Life Sciences WVE Total Equity

Total Equity at other companies

Eli LillyLLY

$31.2B+97.9%

Sarepta Therapeutics, Inc.SRPT

$1.51B+31.7%

Ionis PharmaceuticalsIONS

$491.41M+3.3%

Madrigal Pharmaceuticals, Inc.MDGL

$543.45M-23.5%

ALN

Alnylam PharmaceuticalsALNY

$1.08B+152%

Beam TherapeuticsBEAM

$1.16B+3.1%

Other financials

Income statement

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Balance sheet

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total assets$583.5M+102%

Cash flow

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Valuation

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Profitability

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Returns & leverage

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Wave Life Sciences's total equity?: Wave Life Sciences (WVE) reported total equity of $511.73M in Q1 2026.
How has Wave Life Sciences's total equity changed year-over-year?: Wave Life Sciences's total equity increased by 197.9% year-over-year, from $171.8M to $511.73M.
What is the long-term trend for Wave Life Sciences's total equity?: Over 5 years (2020 to 2025), Wave Life Sciences's total equity has grown at a 44.3% compound annual growth rate (CAGR), from $82.78M to $518.36M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.